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Eeperfusion Strategies
n Acute ST-Segment
levation Myocardial Infarction
cute Angioplasty May Be Feasible
or the Majority of U.S. Citizens
ecently, Boden et al. (1) published a comprehensive review on
eperfusion strategies in acute ST-segment elevation myocardial
nfarction (STEMI). The review favors fibrinolysis in preference to
rimary percutaneous coronary intervention (PPCI) in the case of
percutaneous coronary intervention (PCI)-related delay (extra
elay anticipated when considering PPCI instead of fibrinolysis)
60 min or symptom duration 3 h and state that “transport
elays commonly limit the benefit of PPCI.” Furthermore, the
uthors recommend fibrinolysis particularly in the pre-hospital
etting. There is, however, no evidence to support fibrinolysis in
ny of the aforementioned cases.
The idea of a 60-min maximal acceptable PCI-related delay is
ased on a previous meta-analysis by Nallamothu et al. (2), which
ncluded 23 randomized trials comparing fibrinolysis versus pri-
ary PCI. For each trial, they plotted the mortality benefit
chieved by PPCI compared with fibrinolysis according to the
bserved PCI-related delay. Then, they performed a regression
ine and found that the intercept with the x-axis was approximately
0 min and concluded that fibrinolysis would be superior to PPCI
f the extra delay used to perform PPCI exceeded 60 min.
However, Nallamothu et al. (2) plotted the PCI-related delay
or the PRAGUE-1 (PRimary Angioplasty in patients transferred
rom General community hospitals to specialized PTCA Units
ith or without Emergency thrombolysis) study to be 10 min and
or the PRAGUE-2 study to be 32 min (2). According to the
riginal publications, the PCI-related delay was 70 and 85 min in
he 2 trials, respectively (3,4) In addition, they plotted the
CI-related delay to be 7 min for a study by Ribicini et al. (5), 15
in for a study by Garcı´a et al. (6), 25 min for a study by Gibbons
t al. (7), and 15 min for a study by Vermeer et al. (8). According
o the original articles, the correct PCI-related delays were 16, 47,
5, and 90 min, respectively (5–8).
Finally, the PCI-related delay for the DANAMI-2 trial was
lotted as 55 min. The PCI-related delay, however, varies consid-
rably between nontransfer and transfer patients, and DANAMI-2
ata should be split accordingly (e.g., into a nontransfer and
ransfer group) (9). If one repeats the regression analysis, including
he original tabulated data and splitting the DANAMI-2 data into
transfer and a nontransfer group, then the x-axis intercept
ecomes 120 min. A more proper meta-analysis, however, has
lready been performed by Boersma et al. (10), who included data
t center-level. Accordingly, 153 values instead of 23 values for the
ssociation between PCI-related delay and mortality were imple-
ented in the Boersma et al. (10) meta-analysis, and they foundhat, even at a PCI-related delay of 80 to 120 min, there was a
enefit of PPCI in preference to fibrinolysis.
Regarding the optimal reperfusion therapy in the early incom-
rs, Boden et al. (1) refer to a previous subanalysis of the CAPTIM
Comparison of Angioplasty and Prehospital Thrombolysis in
cute Myocardial Infarction) trial that demonstrated a greater
ortality in PCI-treated patients compared with fibrinolytic-
reated patients who received reperfusion therapy within 3 h of
ymptom duration (11). The CAPTIM data, however, should be
nterpreted cautiously because: 1) the trial was stopped before
cheduled because of a lack of funding, thus hampering the power
f the study; 2) there was no significant difference between the
rimary end point in the main study and thus no reason to perform
ubgroup analysis; and 3) the authors might as well have compared
ortality in PCI patients treated early versus late and then found
hat mortality was greatest in the group treated early.
Again, Boersma et al. (10) have provided us with the best-
vailable evidence, performing the only meta-analysis so far based
n individual data from patients included in 22 studies comparing
PCI with fibrinolysis. The Boersma et al. (10) meta-analysis
ocuments that fibrinolysis is not superior to PPCI in the early
resenters and that lower mortality was observed in PPCI-treated
atients compared with fibrinolysis-treated patients.
Regarding the “limited benefit of PPCI due to transport delays”
nd recommendation of pre-hospital fibrinolysis, a feasible logistic
ay be to implement pre-hospital diagnostic strategies combined
ith rerouting of patients directly to catheterization laboratories.
his strategy reduces the delay in initiation of PPCI by up to 90
in (12) and would considerably increase the catchment areas to
nterventional hospitals. Given that 80% of American citizens live
ithin 60 min of transport to a PPCI hospital and that the
stimated median transportation time to the invasive hospital is 11
in, this strategy would enable PPCI to be the preferred reper-
usion therapy in the majority of STEMI patients (13).
In conclusion, the maximal acceptable PCI-related may be at
east 80 to 120 min, there is no evidence to support fibrinolysis in
he early incomers, and a pre-hospital diagnostic strategy com-
ined with rerouting of STEMI patients directly to catheterization
aboratories would ensure that the majority of American citizens
ould be treated with PPCI in the case of STEMI.
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eply
e appreciate the perspectives offered by Drs. Terkelsen and
ielsen regarding the optimal approach to achieving timely reper-
usion for acute ST-segment elevation myocardial infarction
STEMI). In our review (1), we strongly favored the view that
rimary percutaneous coronary intervention (PCI) represents the
est modality of reperfusion in STEMI patients and, in a perfect
orld with no resource limitations or cost restraints, would be the
reatment of choice for all STEMI patients. However, we at-
empted to address the “real-world” challenges that exist within the
.S., where 1) fully one-third of all STEMI patients currently
eceive no reperfusion (fibrinolytic or mechanical) acutely; 2) theajority of STEMI patients (60% to 70%) present initially to
on-PCI-capable hospitals, which creates inevitable transport
elays to PCI-capable facilities that are frequently beyond the
ontrol of emergency medicine physicians and cardiologists; 3) the
roup of “transfer-in” STEMI patients to PCI-capable hospitals
arely achieve door-to-balloon (DTB) times of90 min (only 8%,
ccording to the Chakrabarti et al. [2] recent analysis of the
ational Registry of Myocardial Infarction); and 4) among
TEMI patients who present within 3 h of initial STEMI
ymptom-onset, there is no clear advantage of a mechanical
eperfusion strategy over a pharmacologic reperfusion strategy,
hich form the basis for the current American College of
ardiology/American Heart Association clinical practice guideline
ecommendations that, in such patients, either reperfusion ap-
roach is considered a Class IA recommendation (3).
Our goal in this review (1) was to address primarily the
anagement issues confronting acute STEMI management in
atients presenting to community hospitals without on-site PCI
apability. In such settings, both emergency medicine physicians
nd cardiologists must quickly decide whether urgent transport to
PCI-capable hospital can likely achieve prompt reperfusion with
DTB 90 min or, alternatively, whether the use of a bolus
brinolytic agent (in a patient without evident contraindications)
ould be a more appropriate reperfusion strategy. If, in fact, 92%
f all such STEMI patients who require urgent transfer for
rimary PCI do not achieve DTB times 90 min, it seems
easonable to consider a pharmacologic reperfusion approach,
ecause there is an almost a 40% relative increase in 30-day
ortality among patients in whom reperfusion is delayed beyond
20 min.
Although both regional and national initiatives are presently
nderway within the U.S. to streamline and expedite STEMI
anagement by using enhanced, field-based electrocardiogram
iagnosis to bypass community hospitals without on-site PCI
apability and instead direct such patients de novo to PCI-capable
ospitals, these efforts are not yet widely developed in many
ommunities and inherently conflict with existing Emergency
edical Service infrastructure nationwide, which continues to
spouse the transport of myocardial infarction patients to the
losest hospital. Accordingly, unlike most of European countries,
here there is more highly coordinated and expedited STEMI
ransport to PCI-capable facilities, the logistical limitations that
ontinue to exist within the U.S. regarding triage and transport of
TEMI patients represent formidable barriers to expanding and
chieving a more broad-based system of primary PCI for all
TEMI patients.
Therefore, we believe our review highlights the need for both
echanical and pharmacologic reperfusion, as dictated by local
esource availability, as the best overall approach to expediting
imely reperfusion in patients who present with STEMI to either
ural or urban hospitals where differential systems and processes of
are may influence clinical decision-making.
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